SLC5A2 and chronic kidney disease: This benefit is in addition to the significant reduction in heart failure events seen with sotagliflozin and other SGLT inhibitors, as well as the significant reduction in major adverse CV events seen with sotagliflozin,4 although not consistently seen with the more selective SGLT2 inhibitors in the CKD trials.